N López-Ariztegui, M Mata-Alvarez Santullano, I Tegel, F Almeida, P Sarasa, R Rojo, F Rico-Villademoros, J Abril-Jaramillo, P Bermejo, C Borrue, N Caballol, M Campins-Romeu, P Clavero, J García-Caldentey, V Gómez-Mayordomo, C Labandeira, G Martí-Andrés, J C Martínez-Castrillo, J Martinez-Poles, T Muñoz, J M Salom, C Valderrama-Martín, A Vinagre-Aragón
Opicapone is a catechol-O-methyl-transferase (iCOMT) inhibitor authorized in Europe in 2016 and indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. The efficacy of opicapone in these patients has been demonstrated in two pivotal randomized clinical trials, BIPARK I and BIPARK II, in which it has demonstrated its superiority versus placebo and non-inferiority versus entacapone...
December 24, 2021: Revista de Neurologia